Apnimed, Inc.
APMD · NASDAQ · USD
15,81USD
+0,71 (+4,70 %)Stand 9. Nov., 21:00
Nachbörslich16,04+0,23 (+1,45 %)19:30 ET
Kennzahlen
- Eröffnung
- 15,32
- Vortag
- 15,10
- Tagesspanne
- 15,09 – 16,22
- 52 Wochen
- 13,88 – 35,29
- Volumen
- 290.121
- Ø Volumen
- 492.112
- Börsenwert
- 658,18 Mio. $
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 8,0
- Nächste Zahlen
- 8. Dez. 2026
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
60,00
Durchschnitt · +279,51 %
Quartalszahlen
Nächste Zahlen: 8. Dez. 2026| Sept. 2026 | |
|---|---|
| Gewinn je Aktie · Erwartet | -0,49 |
| Gewinn je Aktie · Tatsächlich | 3,92 |
| Abweichung | +905,47 % |
| Umsatz · Tatsächlich | 12,08 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
- Morningside Venture Investments Ltd3. Aug. 2026 · 10 percent ownerKauf312.500 Aktien · 16,00
- Morningside Venture Investments Ltd3. Aug. 2026 · 10 percent ownerKauf6,84 Mio. Aktien
- Morningside Venture Investments Ltd3. Aug. 2026 · 10 percent ownerKauf6,84 Mio. Aktien
- Morningside Venture Investments Ltd3. Aug. 2026 · 10 percent ownerKauf75.624 Aktien
- Morningside Venture Investments Ltd3. Aug. 2026 · 10 percent ownerKauf75.624 Aktien · 14,40
- Morningside Venture Investments Ltd3. Aug. 2026 · 10 percent ownerVerkauf1,09 Mio. Aktien · 14,40
- Morningside Venture Investments Ltd3. Aug. 2026 · 10 percent ownerVerkauf6,84 Mio. Aktien
- Morningside Venture Investments Ltd3. Aug. 2026 · 10 percent ownerVerkauf75.624 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Führung
- Lawrence G. MillerFounder & Vice Chair of the Board
- Dennis MolnarPresident & COO
- Kevin Robert LindCEO & Director
- Michael KellyChief Financial Officer
- Steven W. SpectorChief Legal Officer & Head of Corporate Affairs
- Jennifer PattersonSenior Vice President of Human Resources
- CEO
- Kevin R. Lind
- Mitarbeitende
- 81
- Hauptsitz
- Cambridge, MA, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 29. Juli 2026
- Website
- apnimed.com
Nachrichten
- GlobeNewsWire · 5. Nov., 16:05Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewsWire · 12. Okt., 16:05Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
- GlobeNewsWire · 2. Okt., 16:05Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Defense World · 1. Okt., 5:41Apnimed, Inc. (NASDAQ:APMD) Stock Short Interest Jumps 55.7%
- Defense World · 22. Sept., 6:15Apnimed, Inc. (NASDAQ:APMD) Given Consensus Rating of “Moderate Buy” by Brokerages
- Seeking Alpha · 10. Sept., 8:40Apnimed: What We Know Heading Into The Feb PDUFA
- GlobeNewsWire · 8. Sept., 16:39Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- GlobeNewsWire · 4. Sept., 16:01Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Defense World · 2. Sept., 1:50Apnimed, Inc.’s Quiet Period Will End on September 9th (NASDAQ:APMD)
- Proactive Investors · 25. Aug., 12:22Apnimed shares surge on bullish BofA initiation
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.